(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 80,106\u00a0 | $ | 42,690\u00a0 | |||||||
Restricted cash - current | 4,689\u00a0 | \u2014\u00a0 | |||||||||
Total current assets | 84,795\u00a0 | 42,690\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 1,427\u00a0 | \u2014\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 86,222\u00a0 | $ | 42,690\u00a0 |
(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 80,106\u00a0 | $ | 42,690\u00a0 | |||||||
Restricted cash - current | 4,689\u00a0 | \u2014\u00a0 | |||||||||
Total current assets | 84,795\u00a0 | 42,690\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 1,427\u00a0 | \u2014\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 86,222\u00a0 | $ | 42,690\u00a0 |
(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 80,106\u00a0 | $ | 42,690\u00a0 | |||||||
Restricted cash - current | 4,689\u00a0 | \u2014\u00a0 | |||||||||
Total current assets | 84,795\u00a0 | 42,690\u00a0 | |||||||||
Other assets: | |||||||||||
Other assets | 1,427\u00a0 | \u2014\u00a0 | |||||||||
Total cash, cash equivalents and restricted cash | $ | 86,222\u00a0 | $ | 42,690\u00a0 |
(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
| Computer hardware | $ | 18,273\u00a0 | $ | 18,036\u00a0 | |||||||
Machinery and equipment(1) | 17,981\u00a0 | 16,451\u00a0 | |||||||||
| Leasehold improvements | 18,980\u00a0 | 18,870\u00a0 | |||||||||
| Furniture and fixtures | 4,874\u00a0 | 4,705\u00a0 | |||||||||
| Work in progress | 330\u00a0 | 308\u00a0 | |||||||||
| Total | 60,438\u00a0 | 58,370\u00a0 | |||||||||
Less accumulated depreciation(2) | (45,027) | (39,397) | |||||||||
| Property and equipment\u2014net | $ | 15,411\u00a0 | $ | 18,973\u00a0 |
(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
| Computer hardware | $ | 18,273\u00a0 | $ | 18,036\u00a0 | |||||||
Machinery and equipment(1) | 17,981\u00a0 | 16,451\u00a0 | |||||||||
| Leasehold improvements | 18,980\u00a0 | 18,870\u00a0 | |||||||||
| Furniture and fixtures | 4,874\u00a0 | 4,705\u00a0 | |||||||||
| Work in progress | 330\u00a0 | 308\u00a0 | |||||||||
| Total | 60,438\u00a0 | 58,370\u00a0 | |||||||||
Less accumulated depreciation(2) | (45,027) | (39,397) | |||||||||
| Property and equipment\u2014net | $ | 15,411\u00a0 | $ | 18,973\u00a0 |
(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
| Software | $ | 27,569\u00a0 | $ | 28,287\u00a0 | |||||||
| Work in progress | 9\u00a0 | 78\u00a0 | |||||||||
| Total | 27,578\u00a0 | 28,365\u00a0 | |||||||||
Less accumulated amortization(1) | (13,153) | (14,387) | |||||||||
| Software\u2014net | $ | 14,425\u00a0 | $ | 13,978\u00a0 |
(in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
| Software | $ | 27,569\u00a0 | $ | 28,287\u00a0 | |||||||
| Work in progress | 9\u00a0 | 78\u00a0 | |||||||||
| Total | 27,578\u00a0 | 28,365\u00a0 | |||||||||
Less accumulated amortization(1) | (13,153) | (14,387) | |||||||||
| Software\u2014net | $ | 14,425\u00a0 | $ | 13,978\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Finance lease costs(1) | $ | 148\u00a0 | $ | 41\u00a0 | $ | 397\u00a0 | $ | 125\u00a0 | |||||||||||||||
Operating lease costs(2) | 1,845\u00a0 | 1,271\u00a0 | 5,362\u00a0 | 4,371\u00a0 | |||||||||||||||||||
| Short-term lease costs | 63\u00a0 | 61\u00a0 | 188\u00a0 | 183\u00a0 | |||||||||||||||||||
Variable lease costs(3) | 199\u00a0 | 203\u00a0 | 481\u00a0 | 498\u00a0 | |||||||||||||||||||
| Sublease income | (559) | (574) | (1,673) | (1,721) | |||||||||||||||||||
| Total net lease costs | $ | 1,696\u00a0 | $ | 1,002\u00a0 | $ | 4,755\u00a0 | $ | 3,456\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2025 | $ | 2,071\u00a0 | $ | 105\u00a0 | $ | 2,176\u00a0 | ||||||||||||||
| 2026 | 7,893\u00a0 | 400\u00a0 | 8,293\u00a0 | |||||||||||||||||
| 2027 | 7,133\u00a0 | 393\u00a0 | 7,526\u00a0 | |||||||||||||||||
| 2028 | 6,744\u00a0 | 362\u00a0 | 7,106\u00a0 | |||||||||||||||||
| 2029 | 6,845\u00a0 | 362\u00a0 | 7,207\u00a0 | |||||||||||||||||
| Thereafter | 16,109\u00a0 | 30\u00a0 | 16,139\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 46,795\u00a0 | 1,652\u00a0 | 48,447\u00a0 | |||||||||||||||||
| Less: interest | 15,765\u00a0 | 400\u00a0 | 16,165\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 31,030\u00a0 | $ | 1,252\u00a0 | $ | 32,282\u00a0 |
| (in thousands) | Total | |||||||
| Remainder fiscal 2025 | $ | 643\u00a0 | ||||||
| 2026 | 2,587\u00a0 | |||||||
| 2027 | 2,180\u00a0 | |||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| Thereafter | 161\u00a0 | |||||||
| Total sublease income | $ | 9,433\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Finance lease costs(1) | $ | 148\u00a0 | $ | 41\u00a0 | $ | 397\u00a0 | $ | 125\u00a0 | |||||||||||||||
Operating lease costs(2) | 1,845\u00a0 | 1,271\u00a0 | 5,362\u00a0 | 4,371\u00a0 | |||||||||||||||||||
| Short-term lease costs | 63\u00a0 | 61\u00a0 | 188\u00a0 | 183\u00a0 | |||||||||||||||||||
Variable lease costs(3) | 199\u00a0 | 203\u00a0 | 481\u00a0 | 498\u00a0 | |||||||||||||||||||
| Sublease income | (559) | (574) | (1,673) | (1,721) | |||||||||||||||||||
| Total net lease costs | $ | 1,696\u00a0 | $ | 1,002\u00a0 | $ | 4,755\u00a0 | $ | 3,456\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2025 | $ | 2,071\u00a0 | $ | 105\u00a0 | $ | 2,176\u00a0 | ||||||||||||||
| 2026 | 7,893\u00a0 | 400\u00a0 | 8,293\u00a0 | |||||||||||||||||
| 2027 | 7,133\u00a0 | 393\u00a0 | 7,526\u00a0 | |||||||||||||||||
| 2028 | 6,744\u00a0 | 362\u00a0 | 7,106\u00a0 | |||||||||||||||||
| 2029 | 6,845\u00a0 | 362\u00a0 | 7,207\u00a0 | |||||||||||||||||
| Thereafter | 16,109\u00a0 | 30\u00a0 | 16,139\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 46,795\u00a0 | 1,652\u00a0 | 48,447\u00a0 | |||||||||||||||||
| Less: interest | 15,765\u00a0 | 400\u00a0 | 16,165\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 31,030\u00a0 | $ | 1,252\u00a0 | $ | 32,282\u00a0 |
| (in thousands) | Total | |||||||
| Remainder fiscal 2025 | $ | 643\u00a0 | ||||||
| 2026 | 2,587\u00a0 | |||||||
| 2027 | 2,180\u00a0 | |||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| Thereafter | 161\u00a0 | |||||||
| Total sublease income | $ | 9,433\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Finance lease costs(1) | $ | 148\u00a0 | $ | 41\u00a0 | $ | 397\u00a0 | $ | 125\u00a0 | |||||||||||||||
Operating lease costs(2) | 1,845\u00a0 | 1,271\u00a0 | 5,362\u00a0 | 4,371\u00a0 | |||||||||||||||||||
| Short-term lease costs | 63\u00a0 | 61\u00a0 | 188\u00a0 | 183\u00a0 | |||||||||||||||||||
Variable lease costs(3) | 199\u00a0 | 203\u00a0 | 481\u00a0 | 498\u00a0 | |||||||||||||||||||
| Sublease income | (559) | (574) | (1,673) | (1,721) | |||||||||||||||||||
| Total net lease costs | $ | 1,696\u00a0 | $ | 1,002\u00a0 | $ | 4,755\u00a0 | $ | 3,456\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2025 | $ | 2,071\u00a0 | $ | 105\u00a0 | $ | 2,176\u00a0 | ||||||||||||||
| 2026 | 7,893\u00a0 | 400\u00a0 | 8,293\u00a0 | |||||||||||||||||
| 2027 | 7,133\u00a0 | 393\u00a0 | 7,526\u00a0 | |||||||||||||||||
| 2028 | 6,744\u00a0 | 362\u00a0 | 7,106\u00a0 | |||||||||||||||||
| 2029 | 6,845\u00a0 | 362\u00a0 | 7,207\u00a0 | |||||||||||||||||
| Thereafter | 16,109\u00a0 | 30\u00a0 | 16,139\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 46,795\u00a0 | 1,652\u00a0 | 48,447\u00a0 | |||||||||||||||||
| Less: interest | 15,765\u00a0 | 400\u00a0 | 16,165\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 31,030\u00a0 | $ | 1,252\u00a0 | $ | 32,282\u00a0 |
| (in thousands) | Operating leases | Finance leases | Total | |||||||||||||||||
| Remainder fiscal 2025 | $ | 2,071\u00a0 | $ | 105\u00a0 | $ | 2,176\u00a0 | ||||||||||||||
| 2026 | 7,893\u00a0 | 400\u00a0 | 8,293\u00a0 | |||||||||||||||||
| 2027 | 7,133\u00a0 | 393\u00a0 | 7,526\u00a0 | |||||||||||||||||
| 2028 | 6,744\u00a0 | 362\u00a0 | 7,106\u00a0 | |||||||||||||||||
| 2029 | 6,845\u00a0 | 362\u00a0 | 7,207\u00a0 | |||||||||||||||||
| Thereafter | 16,109\u00a0 | 30\u00a0 | 16,139\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Total undiscounted lease payments | 46,795\u00a0 | 1,652\u00a0 | 48,447\u00a0 | |||||||||||||||||
| Less: interest | 15,765\u00a0 | 400\u00a0 | 16,165\u00a0 | |||||||||||||||||
| \u00a0\u00a0\u00a0\u00a0\u00a0Present value of lease liabilities | $ | 31,030\u00a0 | $ | 1,252\u00a0 | $ | 32,282\u00a0 |
| (in thousands) | Total | |||||||
| Remainder fiscal 2025 | $ | 643\u00a0 | ||||||
| 2026 | 2,587\u00a0 | |||||||
| 2027 | 2,180\u00a0 | |||||||
| 2028 | 1,931\u00a0 | |||||||
| 2029 | 1,931\u00a0 | |||||||
| Thereafter | 161\u00a0 | |||||||
| Total sublease income | $ | 9,433\u00a0 |
| March 31, 2025 | June 30, 2024 | ||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||||||||||||||||||||
| Customer relationships | $ | 17,492\u00a0 | $ | (12,673) | $ | 4,819\u00a0 | $ | 17,492\u00a0 | $ | (10,936) | $ | 6,556\u00a0 | |||||||||||||||||||||||||||||
| Trade name | 2,680\u00a0 | (2,635) | 45\u00a0 | 2,680\u00a0 | (2,233) | 447\u00a0 | |||||||||||||||||||||||||||||||||||
| Proprietary software | 4,342\u00a0 | (2,131) | 2,211\u00a0 | 4,342\u00a0 | (1,189) | 3,153\u00a0 | |||||||||||||||||||||||||||||||||||
| Non-compete agreements | 100\u00a0 | (77) | 23\u00a0 | 100\u00a0 | (62) | 38\u00a0 | |||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 24,614\u00a0 | $ | (17,516) | $ | 7,098\u00a0 | $ | 24,614\u00a0 | $ | (14,420) | $ | 10,194\u00a0 |
| Trade Name | Proprietary Software | Non-compete agreements | Customer relationships | Total | |||||||||||||||||||||||||
| Remainder fiscal 2025 | $ | 45\u00a0 | $ | 286\u00a0 | $ | 5\u00a0 | $ | 579\u00a0 | $ | 915\u00a0 | |||||||||||||||||||
| 2026 | \u2014\u00a0 | 1,100\u00a0 | 18\u00a0 | 2,313\u00a0 | 3,431\u00a0 | ||||||||||||||||||||||||
| 2027 | \u2014\u00a0 | 825\u00a0 | \u2014\u00a0 | 1,927\u00a0 | 2,752\u00a0 | ||||||||||||||||||||||||
| Total | $ | 45\u00a0 | $ | 2,211\u00a0 | $ | 23\u00a0 | $ | 4,819\u00a0 | $ | 7,098\u00a0 |
| March 31, 2025 | June 30, 2024 | ||||||||||||||||||||||||||||||||||||||||
| Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | Gross Carrying Amount | Accumulated Amortization | Net Carrying Amount | ||||||||||||||||||||||||||||||||||||
| Customer relationships | $ | 17,492\u00a0 | $ | (12,673) | $ | 4,819\u00a0 | $ | 17,492\u00a0 | $ | (10,936) | $ | 6,556\u00a0 | |||||||||||||||||||||||||||||
| Trade name | 2,680\u00a0 | (2,635) | 45\u00a0 | 2,680\u00a0 | (2,233) | 447\u00a0 | |||||||||||||||||||||||||||||||||||
| Proprietary software | 4,342\u00a0 | (2,131) | 2,211\u00a0 | 4,342\u00a0 | (1,189) | 3,153\u00a0 | |||||||||||||||||||||||||||||||||||
| Non-compete agreements | 100\u00a0 | (77) | 23\u00a0 | 100\u00a0 | (62) | 38\u00a0 | |||||||||||||||||||||||||||||||||||
| Total intangible assets | $ | 24,614\u00a0 | $ | (17,516) | $ | 7,098\u00a0 | $ | 24,614\u00a0 | $ | (14,420) | $ | 10,194\u00a0 |
| Trade Name | Proprietary Software | Non-compete agreements | Customer relationships | Total | |||||||||||||||||||||||||
| Remainder fiscal 2025 | $ | 45\u00a0 | $ | 286\u00a0 | $ | 5\u00a0 | $ | 579\u00a0 | $ | 915\u00a0 | |||||||||||||||||||
| 2026 | \u2014\u00a0 | 1,100\u00a0 | 18\u00a0 | 2,313\u00a0 | 3,431\u00a0 | ||||||||||||||||||||||||
| 2027 | \u2014\u00a0 | 825\u00a0 | \u2014\u00a0 | 1,927\u00a0 | 2,752\u00a0 | ||||||||||||||||||||||||
| Total | $ | 45\u00a0 | $ | 2,211\u00a0 | $ | 23\u00a0 | $ | 4,819\u00a0 | $ | 7,098\u00a0 |
| (in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
| Revolving credit facility | $ | \u2014\u00a0 | $ | \u2014\u00a0 | |||||||
Term Loans | 316,860\u00a0 | 688,203\u00a0 | |||||||||
Class A Notes | 52,966\u00a0 | \u2014\u00a0 | |||||||||
Class B Notes | 35,311\u00a0 | \u2014\u00a0 | |||||||||
| Unamortized debt issuance costs and debt discount | (13,653) | (4,869) | |||||||||
| Total debt | 391,484\u00a0 | 683,334\u00a0 | |||||||||
| Less current portion of long-term debt: | (28,991) | (45,854) | |||||||||
| Long-term debt | $ | 362,493\u00a0 | $ | 637,480\u00a0 |
| (in thousands) | Remainder fiscal 2025 | 2026 | 2027 | 2028 | 2029 | Total | ||||||||||||||
Revolving credit facility | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | ||||||||
| Term Loans | 3,573\u00a0 | 54,001\u00a0 | 13,128\u00a0 | 246,158\u00a0 | \u2014\u00a0 | 316,860\u00a0 | ||||||||||||||
Class A Notes | 2,912\u00a0 | 11,717\u00a0 | 10,593\u00a0 | 8,650\u00a0 | 19,094\u00a0 | 52,966\u00a0 | ||||||||||||||
Class B Notes | 1,942\u00a0 | 7,811\u00a0 | 7,062\u00a0 | 5,767\u00a0 | 12,729\u00a0 | 35,311\u00a0 | ||||||||||||||
| Total obligations | $ | 8,427\u00a0 | $ | 73,529\u00a0 | $ | 30,783\u00a0 | $ | 260,575\u00a0 | $ | 31,823\u00a0 | $ | 405,137\u00a0 |
| (in thousands) | March 31, 2025 | June 30, 2024 | |||||||||
| Revolving credit facility | $ | \u2014\u00a0 | $ | \u2014\u00a0 | |||||||
Term Loans | 316,860\u00a0 | 688,203\u00a0 | |||||||||
Class A Notes | 52,966\u00a0 | \u2014\u00a0 | |||||||||
Class B Notes | 35,311\u00a0 | \u2014\u00a0 | |||||||||
| Unamortized debt issuance costs and debt discount | (13,653) | (4,869) | |||||||||
| Total debt | 391,484\u00a0 | 683,334\u00a0 | |||||||||
| Less current portion of long-term debt: | (28,991) | (45,854) | |||||||||
| Long-term debt | $ | 362,493\u00a0 | $ | 637,480\u00a0 |
| (in thousands) | Remainder fiscal 2025 | 2026 | 2027 | 2028 | 2029 | Total | ||||||||||||||
Revolving credit facility | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | ||||||||
| Term Loans | 3,573\u00a0 | 54,001\u00a0 | 13,128\u00a0 | 246,158\u00a0 | \u2014\u00a0 | 316,860\u00a0 | ||||||||||||||
Class A Notes | 2,912\u00a0 | 11,717\u00a0 | 10,593\u00a0 | 8,650\u00a0 | 19,094\u00a0 | 52,966\u00a0 | ||||||||||||||
Class B Notes | 1,942\u00a0 | 7,811\u00a0 | 7,062\u00a0 | 5,767\u00a0 | 12,729\u00a0 | 35,311\u00a0 | ||||||||||||||
| Total obligations | $ | 8,427\u00a0 | $ | 73,529\u00a0 | $ | 30,783\u00a0 | $ | 260,575\u00a0 | $ | 31,823\u00a0 | $ | 405,137\u00a0 |
As of March\u00a031, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 318\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 318\u00a0 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 112,838\u00a0 | $ | 112,838\u00a0 |
As of June 30, 2024 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 307\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 307\u00a0 | |||||||||||||||
Other current assets | |||||||||||||||||||||||
Cash flow hedge | $ | \u2014\u00a0 | $ | 5,027\u00a0 | $ | \u2014\u00a0 | $ | 5,027\u00a0 |
| March 31, 2025 | ||||||||||||||
Tranche 1 | Tranche 2 | Tranche 3 | Tranche 4 | |||||||||||
Stock price(1) | $ | 3.34\u00a0 | $ | 3.34\u00a0 | $ | 3.34\u00a0 | $ | 3.34\u00a0 | ||||||
| Exercise price | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | ||||||
Expected volatility | 107.01\u00a0 | % | 104.53\u00a0 | % | 104.53\u00a0 | % | 104.53\u00a0 | % | ||||||
Risk-free interest rate | 3.87\u00a0 | % | 3.92\u00a0 | % | 3.99\u00a0 | % | 4.05\u00a0 | % | ||||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | ||||||
Expected life (years) | 4.54 years | 5.54 years | 6.54 years | 7.54 years | ||||||||||
Fair value per warrant | $ | 2.61\u00a0 | $ | 2.72\u00a0 | $ | 2.84\u00a0 | $ | 2.93\u00a0 |
| March 31, 2025 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 3.34\u00a0 | $ | 3.34\u00a0 | $ | 3.34\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
Expected volatility | 104.53\u00a0 | % | 104.53\u00a0 | % | 104.53\u00a0 | % | |||||
Risk-free interest rate | 4.17\u00a0 | % | 4.17\u00a0 | % | 4.17\u00a0 | % | |||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
Expected life (years) | 9.87 years | 9.87 years | 9.87 years | ||||||||
Fair value per warrant | $ | 3.34\u00a0 | $ | 3.04\u00a0 | $ | 2.99\u00a0 |
| (in thousands) | Warrant Liability | ||||
Balance as of June 30, 2024 | $ | \u2014\u00a0 | |||
| Issuance of Eleventh Amendment Warrants | 8,628\u00a0 | ||||
| Issuance of Senior Non-Convertible Preferred Stock Warrants | 128,953\u00a0 | ||||
| Change in fair value | (24,743) | ||||
Balance as of March\u00a031, 2025 | $ | 112,838\u00a0 |
As of March\u00a031, 2025 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 318\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 318\u00a0 | |||||||||||||||
| Liabilities: | |||||||||||||||||||||||
Other long-term liabilities | |||||||||||||||||||||||
| Warrant liability | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 112,838\u00a0 | $ | 112,838\u00a0 |
As of June 30, 2024 | |||||||||||||||||||||||
| (in thousands) | Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||
Assets: | |||||||||||||||||||||||
Cash equivalents | |||||||||||||||||||||||
Money market funds | $ | 307\u00a0 | $ | \u2014\u00a0 | $ | \u2014\u00a0 | $ | 307\u00a0 | |||||||||||||||
Other current assets | |||||||||||||||||||||||
Cash flow hedge | $ | \u2014\u00a0 | $ | 5,027\u00a0 | $ | \u2014\u00a0 | $ | 5,027\u00a0 |
| March 31, 2025 | ||||||||||||||
Tranche 1 | Tranche 2 | Tranche 3 | Tranche 4 | |||||||||||
Stock price(1) | $ | 3.34\u00a0 | $ | 3.34\u00a0 | $ | 3.34\u00a0 | $ | 3.34\u00a0 | ||||||
| Exercise price | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | $ | 3.00\u00a0 | ||||||
Expected volatility | 107.01\u00a0 | % | 104.53\u00a0 | % | 104.53\u00a0 | % | 104.53\u00a0 | % | ||||||
Risk-free interest rate | 3.87\u00a0 | % | 3.92\u00a0 | % | 3.99\u00a0 | % | 4.05\u00a0 | % | ||||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | ||||||
Expected life (years) | 4.54 years | 5.54 years | 6.54 years | 7.54 years | ||||||||||
Fair value per warrant | $ | 2.61\u00a0 | $ | 2.72\u00a0 | $ | 2.84\u00a0 | $ | 2.93\u00a0 |
| March 31, 2025 | |||||||||||
| Tranche A | Tranche B | Tranche C | |||||||||
Stock price(1) | $ | 3.34\u00a0 | $ | 3.34\u00a0 | $ | 3.34\u00a0 | |||||
| Exercise price | $ | 0.01\u00a0 | $ | 3.92\u00a0 | $ | 5.50\u00a0 | |||||
Expected volatility | 104.53\u00a0 | % | 104.53\u00a0 | % | 104.53\u00a0 | % | |||||
Risk-free interest rate | 4.17\u00a0 | % | 4.17\u00a0 | % | 4.17\u00a0 | % | |||||
Expected dividend-yield | \u2014\u00a0 | % | \u2014\u00a0 | % | \u2014\u00a0 | % | |||||
Expected life (years) | 9.87 years | 9.87 years | 9.87 years | ||||||||
Fair value per warrant | $ | 3.34\u00a0 | $ | 3.04\u00a0 | $ | 2.99\u00a0 |
| (in thousands) | Warrant Liability | ||||
Balance as of June 30, 2024 | $ | \u2014\u00a0 | |||
| Issuance of Eleventh Amendment Warrants | 8,628\u00a0 | ||||
| Issuance of Senior Non-Convertible Preferred Stock Warrants | 128,953\u00a0 | ||||
| Change in fair value | (24,743) | ||||
Balance as of March\u00a031, 2025 | $ | 112,838\u00a0 |
| ESPP | 159\u00a0 | |||||||
| Stock awards outstanding under 2020 Plan | 18,932,801\u00a0 | |||||||
| Stock awards available for grant under 2020 Plan | 3,581,792\u00a0 | |||||||
| Options outstanding under 2003 Plan | 428,567\u00a0 | |||||||
| Total | 22,943,319\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Share-based compensation related to: | ||||||||||||||||||||||||||
| Equity classified stock options | $ | 376\u00a0 | $ | 673\u00a0 | $ | 1,226\u00a0 | $ | 2,109\u00a0 | ||||||||||||||||||
| Equity classified RSU's | 2,611\u00a0 | 1,992\u00a0 | 7,546\u00a0 | 5,850\u00a0 | ||||||||||||||||||||||
| Equity classified PSU's | \u2014\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 33\u00a0 | ||||||||||||||||||||||
| Equity classified PVU's | 1,973\u00a0 | 850\u00a0 | 4,733\u00a0 | 2,520\u00a0 | ||||||||||||||||||||||
| Total | $ | 4,960\u00a0 | $ | 3,515\u00a0 | $ | 13,505\u00a0 | $ | 10,512\u00a0 |
| Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (in Years) | Aggregate Intrinsic Value (in Thousands) | |||||||||||
Outstanding\u2014June\u00a030, 2024 | 3,677,964\u00a0 | $ | 11.81\u00a0 | |||||||||||
| Options granted | \u2014\u00a0 | \u2014\u00a0 | ||||||||||||
| Options exercised | (153,480) | 2.12\u00a0 | ||||||||||||
| Options forfeited/expired/cancelled | (178,840) | 10.59\u00a0 | ||||||||||||
Outstanding\u2014March\u00a031, 2025 | 3,345,644\u00a0 | $ | 12.32\u00a0 | 5.70 | $ | 1,340\u00a0 | ||||||||
Vested and exercisable\u2014March\u00a031, 2025 | 2,886,086\u00a0 | $ | 12.64\u00a0 | 5.55 | $ | 1,162\u00a0 |
| Number of Restricted Stock Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2024 | 8,441,168\u00a0 | $ | 1.91\u00a0 | ||||||||
| Granted | 4,017,181\u00a0 | 2.99\u00a0 | |||||||||
| Vested | (3,640,363) | 2.10\u00a0 | |||||||||
| Forfeited | (284,075) | 2.70\u00a0 | |||||||||
Unvested as of March\u00a031, 2025 | 8,533,911\u00a0 | $ | 2.31\u00a0 |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 772,027\u00a0 | $ | 3.98\u00a0 | $ | 3.13\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 772,020\u00a0 | $ | 3.75\u00a0 | $ | 6.00\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 772,027\u00a0 | $ | 3.49\u00a0 | $ | 9.00\u00a0 | August 1, 2024 - August 1, 2029 | 1.31 years - 3 years |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 559,202\u00a0 | $ | 1.85\u00a0 | $ | 2.50\u00a0 | August 1, 2023 - August 1, 2028 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 559,175\u00a0 | $ | 1.69\u00a0 | $ | 5.00\u00a0 | August 1, 2023 - August 1, 2028 | 1.41 years - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 559,213\u00a0 | $ | 1.55\u00a0 | $ | 7.50\u00a0 | August 1, 2023 - August 1, 2028 | 1.96 years - 3 years | |||||||||||||||||||||||||
| Tranche 4 | 559,185\u00a0 | $ | 1.45\u00a0 | $ | 10.00\u00a0 | August 1, 2023 - August 1, 2028 | 2.27 years - 3 years | |||||||||||||||||||||||||
| Tranche 5 | 8,439\u00a0 | $ | 0.98\u00a0 | $ | 2.50\u00a0 | February 1, 2024 - February 1, 2029 | 1.29 years - 3 years | |||||||||||||||||||||||||
| Tranche 6 | 8,437\u00a0 | $ | 0.84\u00a0 | $ | 5.00\u00a0 | February 1, 2024 - February 1, 2029 | 2.20 years - 3 years | |||||||||||||||||||||||||
| Tranche 7 | 8,441\u00a0 | $ | 0.75\u00a0 | $ | 7.50\u00a0 | February 1, 2024 - February 1, 2029 | 2.64 years- 3 years | |||||||||||||||||||||||||
| Tranche 8 | 8,438\u00a0 | $ | 0.67\u00a0 | $ | 10.00\u00a0 | February 1, 2024 - February 1, 2029 | 2.90 years - 3 years |
| Shares Granted August 1, 2024 | Shares Granted February 1, 2024 | Shares Granted August 1, 2023 | ||||||||||||||||||
| Share price as of grant date | $4.01 | $1.11 | $1.38 | |||||||||||||||||
| Volatility | 88.8% | 90.8% | 94.3% | |||||||||||||||||
| Risk-free interest rate | 3.8% | 3.7% | 4.1% | |||||||||||||||||
| Cost of Equity | 12.6% | 11.6% | 9.2% | |||||||||||||||||
| Dividend yield | \u2014% | \u2014% | \u2014% |
| Number of Price-Vested Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2024 | 6,170,385\u00a0 | $ | 1.37\u00a0 | ||||||||
| Granted | 2,316,074\u00a0 | 3.74 | |||||||||
| Vested | (831,224) | 1.32\u00a0 | |||||||||
| Forfeited | (173,422) | 2.01\u00a0 | |||||||||
Unvested as of March\u00a031, 2025 | 7,481,813\u00a0 | $ | 2.11\u00a0 |
| ESPP | 159\u00a0 | |||||||
| Stock awards outstanding under 2020 Plan | 18,932,801\u00a0 | |||||||
| Stock awards available for grant under 2020 Plan | 3,581,792\u00a0 | |||||||
| Options outstanding under 2003 Plan | 428,567\u00a0 | |||||||
| Total | 22,943,319\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Share-based compensation related to: | ||||||||||||||||||||||||||
| Equity classified stock options | $ | 376\u00a0 | $ | 673\u00a0 | $ | 1,226\u00a0 | $ | 2,109\u00a0 | ||||||||||||||||||
| Equity classified RSU's | 2,611\u00a0 | 1,992\u00a0 | 7,546\u00a0 | 5,850\u00a0 | ||||||||||||||||||||||
| Equity classified PSU's | \u2014\u00a0 | \u2014\u00a0 | \u2014\u00a0 | 33\u00a0 | ||||||||||||||||||||||
| Equity classified PVU's | 1,973\u00a0 | 850\u00a0 | 4,733\u00a0 | 2,520\u00a0 | ||||||||||||||||||||||
| Total | $ | 4,960\u00a0 | $ | 3,515\u00a0 | $ | 13,505\u00a0 | $ | 10,512\u00a0 |
| Number of Options | Weighted- Average Exercise Price | Weighted- Average Remaining Contractual Term (in Years) | Aggregate Intrinsic Value (in Thousands) | |||||||||||
Outstanding\u2014June\u00a030, 2024 | 3,677,964\u00a0 | $ | 11.81\u00a0 | |||||||||||
| Options granted | \u2014\u00a0 | \u2014\u00a0 | ||||||||||||
| Options exercised | (153,480) | 2.12\u00a0 | ||||||||||||
| Options forfeited/expired/cancelled | (178,840) | 10.59\u00a0 | ||||||||||||
Outstanding\u2014March\u00a031, 2025 | 3,345,644\u00a0 | $ | 12.32\u00a0 | 5.70 | $ | 1,340\u00a0 | ||||||||
Vested and exercisable\u2014March\u00a031, 2025 | 2,886,086\u00a0 | $ | 12.64\u00a0 | 5.55 | $ | 1,162\u00a0 |
| Number of Restricted Stock Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2024 | 8,441,168\u00a0 | $ | 1.91\u00a0 | ||||||||
| Granted | 4,017,181\u00a0 | 2.99\u00a0 | |||||||||
| Vested | (3,640,363) | 2.10\u00a0 | |||||||||
| Forfeited | (284,075) | 2.70\u00a0 | |||||||||
Unvested as of March\u00a031, 2025 | 8,533,911\u00a0 | $ | 2.31\u00a0 |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 772,027\u00a0 | $ | 3.98\u00a0 | $ | 3.13\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 772,020\u00a0 | $ | 3.75\u00a0 | $ | 6.00\u00a0 | August 1, 2024 - August 1, 2029 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 772,027\u00a0 | $ | 3.49\u00a0 | $ | 9.00\u00a0 | August 1, 2024 - August 1, 2029 | 1.31 years - 3 years |
| Number of Shares per Tranche | Grant Date Fair Value (per Share) | Stock Price Hurdle (per Share) | Performance Period | Requisite Service Period | ||||||||||||||||||||||||||||
| Tranche 1 | 559,202\u00a0 | $ | 1.85\u00a0 | $ | 2.50\u00a0 | August 1, 2023 - August 1, 2028 | 1 year - 3 years | |||||||||||||||||||||||||
| Tranche 2 | 559,175\u00a0 | $ | 1.69\u00a0 | $ | 5.00\u00a0 | August 1, 2023 - August 1, 2028 | 1.41 years - 3 years | |||||||||||||||||||||||||
| Tranche 3 | 559,213\u00a0 | $ | 1.55\u00a0 | $ | 7.50\u00a0 | August 1, 2023 - August 1, 2028 | 1.96 years - 3 years | |||||||||||||||||||||||||
| Tranche 4 | 559,185\u00a0 | $ | 1.45\u00a0 | $ | 10.00\u00a0 | August 1, 2023 - August 1, 2028 | 2.27 years - 3 years | |||||||||||||||||||||||||
| Tranche 5 | 8,439\u00a0 | $ | 0.98\u00a0 | $ | 2.50\u00a0 | February 1, 2024 - February 1, 2029 | 1.29 years - 3 years | |||||||||||||||||||||||||
| Tranche 6 | 8,437\u00a0 | $ | 0.84\u00a0 | $ | 5.00\u00a0 | February 1, 2024 - February 1, 2029 | 2.20 years - 3 years | |||||||||||||||||||||||||
| Tranche 7 | 8,441\u00a0 | $ | 0.75\u00a0 | $ | 7.50\u00a0 | February 1, 2024 - February 1, 2029 | 2.64 years- 3 years | |||||||||||||||||||||||||
| Tranche 8 | 8,438\u00a0 | $ | 0.67\u00a0 | $ | 10.00\u00a0 | February 1, 2024 - February 1, 2029 | 2.90 years - 3 years |
| Shares Granted August 1, 2024 | Shares Granted February 1, 2024 | Shares Granted August 1, 2023 | ||||||||||||||||||
| Share price as of grant date | $4.01 | $1.11 | $1.38 | |||||||||||||||||
| Volatility | 88.8% | 90.8% | 94.3% | |||||||||||||||||
| Risk-free interest rate | 3.8% | 3.7% | 4.1% | |||||||||||||||||
| Cost of Equity | 12.6% | 11.6% | 9.2% | |||||||||||||||||
| Dividend yield | \u2014% | \u2014% | \u2014% |
| Number of Price-Vested Units | Weighted-Average Grant Date Fair Value | ||||||||||
Unvested as of June\u00a030, 2024 | 6,170,385\u00a0 | $ | 1.37\u00a0 | ||||||||
| Granted | 2,316,074\u00a0 | 3.74 | |||||||||
| Vested | (831,224) | 1.32\u00a0 | |||||||||
| Forfeited | (173,422) | 2.01\u00a0 | |||||||||
Unvested as of March\u00a031, 2025 | 7,481,813\u00a0 | $ | 2.11\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||
| (dollars in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Senior: | ||||||||||||||||||||||||||
| Medicare advantage commissions | $ | 145,453\u00a0 | $ | 184,740\u00a0 | $ | 446,640\u00a0 | $ | 477,081\u00a0 | ||||||||||||||||||
Other Senior commissions | 3,345\u00a0 | 2,784\u00a0 | 8,111\u00a0 | 7,622\u00a0 | ||||||||||||||||||||||
| Other services | 20,644\u00a0 | 16,735\u00a0 | 63,179\u00a0 | 57,002\u00a0 | ||||||||||||||||||||||
| Total Senior revenue | 169,442\u00a0 | 204,259\u00a0 | 517,930\u00a0 | 541,705\u00a0 | ||||||||||||||||||||||
| Healthcare Services: | ||||||||||||||||||||||||||
| Pharmacy | 185,271\u00a0 | 120,282\u00a0 | 518,154\u00a0 | 323,865\u00a0 | ||||||||||||||||||||||
| Other services | 4,298\u00a0 | 3,925\u00a0 | 10,523\u00a0 | 9,419\u00a0 | ||||||||||||||||||||||
| Total Healthcare Services revenue | 189,569\u00a0 | 124,207\u00a0 | 528,677\u00a0 | 333,284\u00a0 | ||||||||||||||||||||||
| Life: | ||||||||||||||||||||||||||
| Term commissions | 20,139\u00a0 | 17,789\u00a0 | 55,169\u00a0 | 55,016\u00a0 | ||||||||||||||||||||||
| Final expense commissions | 20,188\u00a0 | 17,537\u00a0 | 54,795\u00a0 | 46,139\u00a0 | ||||||||||||||||||||||
| Other services | 5,515\u00a0 | 5,360\u00a0 | 15,029\u00a0 | 14,700\u00a0 | ||||||||||||||||||||||
| Total Life revenue | 45,842\u00a0 | 40,686\u00a0 | 124,993\u00a0 | 115,855\u00a0 | ||||||||||||||||||||||
| All other: | ||||||||||||||||||||||||||
| Commissions | 4,900\u00a0 | 8,746\u00a0 | 14,667\u00a0 | 27,836\u00a0 | ||||||||||||||||||||||
| Other services | 377\u00a0 | 388\u00a0 | 717\u00a0 | 813\u00a0 | ||||||||||||||||||||||
Total All other revenue | 5,277\u00a0 | 9,134\u00a0 | 15,384\u00a0 | 28,649\u00a0 | ||||||||||||||||||||||
| Eliminations: | ||||||||||||||||||||||||||
| Commissions | (867) | (833) | (2,531) | (1,950) | ||||||||||||||||||||||
| Other services | (1,103) | (1,053) | (2,961) | (2,976) | ||||||||||||||||||||||
| Total Elimination revenue | (1,970) | (1,886) | (5,492) | (4,926) | ||||||||||||||||||||||
| Total Commissions and other services revenue | 222,889\u00a0 | 256,118\u00a0 | 663,338\u00a0 | 690,702\u00a0 | ||||||||||||||||||||||
| Total Pharmacy revenue | 185,271\u00a0 | 120,282\u00a0 | 518,154\u00a0 | 323,865\u00a0 | ||||||||||||||||||||||
| Total Revenue | $ | 408,160\u00a0 | $ | 376,400\u00a0 | $ | 1,181,492\u00a0 | $ | 1,014,567\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2024 | $ | 881,317\u00a0 | ||||||
Commission revenue from revenue recognized | 268,465\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | (5,154) | |||||||
| Amounts recognized as accounts receivable, net | (229,545) | |||||||
Balance as of March\u00a031, 2025 | $ | 915,083\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2024 | $ | 8,066\u00a0 | ||||||
Commission and other services revenue recognized | (31,982) | |||||||
| Amounts recognized as contract liabilities | 24,861\u00a0 | |||||||
Balance as of March\u00a031, 2025 | $ | 945\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||||||||
| (dollars in thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||||
| Senior: | ||||||||||||||||||||||||||
| Medicare advantage commissions | $ | 145,453\u00a0 | $ | 184,740\u00a0 | $ | 446,640\u00a0 | $ | 477,081\u00a0 | ||||||||||||||||||
Other Senior commissions | 3,345\u00a0 | 2,784\u00a0 | 8,111\u00a0 | 7,622\u00a0 | ||||||||||||||||||||||
| Other services | 20,644\u00a0 | 16,735\u00a0 | 63,179\u00a0 | 57,002\u00a0 | ||||||||||||||||||||||
| Total Senior revenue | 169,442\u00a0 | 204,259\u00a0 | 517,930\u00a0 | 541,705\u00a0 | ||||||||||||||||||||||
| Healthcare Services: | ||||||||||||||||||||||||||
| Pharmacy | 185,271\u00a0 | 120,282\u00a0 | 518,154\u00a0 | 323,865\u00a0 | ||||||||||||||||||||||
| Other services | 4,298\u00a0 | 3,925\u00a0 | 10,523\u00a0 | 9,419\u00a0 | ||||||||||||||||||||||
| Total Healthcare Services revenue | 189,569\u00a0 | 124,207\u00a0 | 528,677\u00a0 | 333,284\u00a0 | ||||||||||||||||||||||
| Life: | ||||||||||||||||||||||||||
| Term commissions | 20,139\u00a0 | 17,789\u00a0 | 55,169\u00a0 | 55,016\u00a0 | ||||||||||||||||||||||
| Final expense commissions | 20,188\u00a0 | 17,537\u00a0 | 54,795\u00a0 | 46,139\u00a0 | ||||||||||||||||||||||
| Other services | 5,515\u00a0 | 5,360\u00a0 | 15,029\u00a0 | 14,700\u00a0 | ||||||||||||||||||||||
| Total Life revenue | 45,842\u00a0 | 40,686\u00a0 | 124,993\u00a0 | 115,855\u00a0 | ||||||||||||||||||||||
| All other: | ||||||||||||||||||||||||||
| Commissions | 4,900\u00a0 | 8,746\u00a0 | 14,667\u00a0 | 27,836\u00a0 | ||||||||||||||||||||||
| Other services | 377\u00a0 | 388\u00a0 | 717\u00a0 | 813\u00a0 | ||||||||||||||||||||||
Total All other revenue | 5,277\u00a0 | 9,134\u00a0 | 15,384\u00a0 | 28,649\u00a0 | ||||||||||||||||||||||
| Eliminations: | ||||||||||||||||||||||||||
| Commissions | (867) | (833) | (2,531) | (1,950) | ||||||||||||||||||||||
| Other services | (1,103) | (1,053) | (2,961) | (2,976) | ||||||||||||||||||||||
| Total Elimination revenue | (1,970) | (1,886) | (5,492) | (4,926) | ||||||||||||||||||||||
| Total Commissions and other services revenue | 222,889\u00a0 | 256,118\u00a0 | 663,338\u00a0 | 690,702\u00a0 | ||||||||||||||||||||||
| Total Pharmacy revenue | 185,271\u00a0 | 120,282\u00a0 | 518,154\u00a0 | 323,865\u00a0 | ||||||||||||||||||||||
| Total Revenue | $ | 408,160\u00a0 | $ | 376,400\u00a0 | $ | 1,181,492\u00a0 | $ | 1,014,567\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2024 | $ | 881,317\u00a0 | ||||||
Commission revenue from revenue recognized | 268,465\u00a0 | |||||||
| Net commission revenue adjustment from change in estimate | (5,154) | |||||||
| Amounts recognized as accounts receivable, net | (229,545) | |||||||
Balance as of March\u00a031, 2025 | $ | 915,083\u00a0 |
| (in thousands) | ||||||||
Balance as of June\u00a030, 2024 | $ | 8,066\u00a0 | ||||||
Commission and other services revenue recognized | (31,982) | |||||||
| Amounts recognized as contract liabilities | 24,861\u00a0 | |||||||
Balance as of March\u00a031, 2025 | $ | 945\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||
(in thousands, except per share amounts) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||
| Numerator: | ||||||||||||||||||||
| Net income (loss) attributable to common shareholders, basic | $ | 20,235\u00a0 | $ | 8,551\u00a0 | $ | 28,925\u00a0 | $ | (3,108) | ||||||||||||
Change in fair value of warrants(1) | (13,803) | \u2014\u00a0 | (6,160) | \u2014\u00a0 | ||||||||||||||||
| Net income (loss) attributable to common shareholders, diluted | 6,432\u00a0 | 8,551\u00a0 | 22,765\u00a0 | (3,108) | ||||||||||||||||
| Denominator: | ||||||||||||||||||||
| Weighted-average common stock outstanding, basic | 178,156\u00a0 | 169,070\u00a0 | 173,462\u00a0 | 168,291\u00a0 | ||||||||||||||||
Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP(2) | 5,738\u00a0 | 1,886\u00a0 | 4,518\u00a0 | \u2014\u00a0 | ||||||||||||||||
Dilutive effect of warrants to purchase common stock | 2,745\u00a0 | \u2014\u00a0 | 915\u00a0 | \u2014\u00a0 | ||||||||||||||||
Weighted-average common stock outstanding, diluted | 186,639\u00a0 | 170,956\u00a0 | 178,895\u00a0 | 168,291\u00a0 | ||||||||||||||||
| Net income (loss) per share\u2014basic: | $ | 0.11\u00a0 | $ | 0.05\u00a0 | $ | 0.17\u00a0 | $ | (0.02) | ||||||||||||
Net income (loss) per share\u2014diluted: | $ | 0.03\u00a0 | $ | 0.05\u00a0 | $ | 0.13\u00a0 | $ | (0.02) |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Stock options outstanding to purchase shares of common stock, unvested RSU's and shares from the ESPP | 2,161\u00a0 | 6,483\u00a0 | 3,496\u00a0 | 12,145\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Shares subject to outstanding PVU\u2019s | 7,482\u00a0 | 6,244\u00a0 | 7,422\u00a0 | 6,268\u00a0 | |||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Warrants to purchase shares of common stock | 7,241\u00a0 | \u2014\u00a0 | 4,270\u00a0 | \u2014\u00a0 | |||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | |||||||||||||||||||
(in thousands, except per share amounts) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||
| Numerator: | ||||||||||||||||||||
| Net income (loss) attributable to common shareholders, basic | $ | 20,235\u00a0 | $ | 8,551\u00a0 | $ | 28,925\u00a0 | $ | (3,108) | ||||||||||||
Change in fair value of warrants(1) | (13,803) | \u2014\u00a0 | (6,160) | \u2014\u00a0 | ||||||||||||||||
| Net income (loss) attributable to common shareholders, diluted | 6,432\u00a0 | 8,551\u00a0 | 22,765\u00a0 | (3,108) | ||||||||||||||||
| Denominator: | ||||||||||||||||||||
| Weighted-average common stock outstanding, basic | 178,156\u00a0 | 169,070\u00a0 | 173,462\u00a0 | 168,291\u00a0 | ||||||||||||||||
Stock options outstanding to purchase shares of common stock including unvested RSU's and from the ESPP(2) | 5,738\u00a0 | 1,886\u00a0 | 4,518\u00a0 | \u2014\u00a0 | ||||||||||||||||
Dilutive effect of warrants to purchase common stock | 2,745\u00a0 | \u2014\u00a0 | 915\u00a0 | \u2014\u00a0 | ||||||||||||||||
Weighted-average common stock outstanding, diluted | 186,639\u00a0 | 170,956\u00a0 | 178,895\u00a0 | 168,291\u00a0 | ||||||||||||||||
| Net income (loss) per share\u2014basic: | $ | 0.11\u00a0 | $ | 0.05\u00a0 | $ | 0.17\u00a0 | $ | (0.02) | ||||||||||||
Net income (loss) per share\u2014diluted: | $ | 0.03\u00a0 | $ | 0.05\u00a0 | $ | 0.13\u00a0 | $ | (0.02) |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
Stock options outstanding to purchase shares of common stock, unvested RSU's and shares from the ESPP | 2,161\u00a0 | 6,483\u00a0 | 3,496\u00a0 | 12,145\u00a0 |
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Shares subject to outstanding PVU\u2019s | 7,482\u00a0 | 6,244\u00a0 | 7,422\u00a0 | 6,268\u00a0 | |||||||||||||||||||
| Three Months Ended March 31, | Nine Months Ended March 31, | ||||||||||||||||||||||
| (in thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Warrants to purchase shares of common stock | 7,241\u00a0 | \u2014\u00a0 | 4,270\u00a0 | \u2014\u00a0 | |||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 167,565\u00a0 | $ | 189,496\u00a0 | $ | 45,822\u00a0 | $ | 402,883\u00a0 | |||||||||||||||
| Intersegment revenue | 1,877\u00a0 | 73\u00a0 | 20\u00a0 | 1,970\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 169,442\u00a0 | $ | 189,569\u00a0 | $ | 45,842\u00a0 | $ | 404,853\u00a0 | |||||||||||||||
All other revenue | 5,277\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (1,970) | ||||||||||||||||||||||
Total consolidated revenue | $ | 408,160\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| Adjusted Segment EBITDA | $ | 45,701\u00a0 | $ | 6,445\u00a0 | $ | 6,364\u00a0 | $ | 58,510\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 3,549\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (24,336) | ||||||||||||||||||||||
| Share-based compensation expense | (4,960) | ||||||||||||||||||||||
Transaction costs (1) | (5,813) | ||||||||||||||||||||||
| Depreciation and amortization | (4,925) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (3) | ||||||||||||||||||||||
Change in fair value of warrants | 32,986\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (20,407) | ||||||||||||||||||||||
Income before income tax expense (benefit) | $ | 34,601\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 202,399\u00a0 | $ | 124,207\u00a0 | $ | 40,660\u00a0 | $ | 367,266\u00a0 | |||||||||||||||
| Intersegment revenue | 1,860\u00a0 | \u2014\u00a0 | 26\u00a0 | 1,886\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 204,259\u00a0 | $ | 124,207\u00a0 | $ | 40,686\u00a0 | $ | 369,152\u00a0 | |||||||||||||||
All other revenue | 9,134\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (1,886) | ||||||||||||||||||||||
Total consolidated revenue | $ | 376,400\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Adjusted Segment EBITDA | $ | 61,494\u00a0 | $ | 1,609\u00a0 | $ | 3,138\u00a0 | $ | 66,241\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 3,609\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (23,252) | ||||||||||||||||||||||
| Share-based compensation expense | (3,515) | ||||||||||||||||||||||
Transaction costs (1) | (3,325) | ||||||||||||||||||||||
| Depreciation and amortization | (6,704) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (4) | ||||||||||||||||||||||
Interest expense, net | (24,330) | ||||||||||||||||||||||
Income before income tax expense (benefit) | $ | 8,720\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 512,735\u00a0 | $ | 528,443\u00a0 | $ | 124,930\u00a0 | $ | 1,166,108\u00a0 | |||||||||||||||
| Intersegment revenue | 5,195\u00a0 | 234\u00a0 | 63\u00a0 | 5,492\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 517,930\u00a0 | $ | 528,677\u00a0 | $ | 124,993\u00a0 | $ | 1,171,600\u00a0 | |||||||||||||||
All other revenue | 15,384\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (5,492) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,181,492\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| Adjusted Segment EBITDA | $ | 153,949\u00a0 | $ | 13,534\u00a0 | $ | 19,747\u00a0 | $ | 187,230\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 9,645\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (73,316) | ||||||||||||||||||||||
| Share-based compensation expense | (13,505) | ||||||||||||||||||||||
Transaction costs (1) | (13,358) | ||||||||||||||||||||||
| Depreciation and amortization | (15,584) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (160) | ||||||||||||||||||||||
Change in fair value of warrants | 25,344\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (67,160) | ||||||||||||||||||||||
Income before income tax expense (benefit) | $ | 39,136\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 536,857\u00a0 | $ | 333,284\u00a0 | $ | 115,777\u00a0 | $ | 985,918\u00a0 | |||||||||||||||
| Intersegment revenue | 4,848\u00a0 | \u2014\u00a0 | 78\u00a0 | 4,926\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 541,705\u00a0 | $ | 333,284\u00a0 | $ | 115,855\u00a0 | $ | 990,844\u00a0 | |||||||||||||||
All other revenue | 28,649\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (4,926) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,014,567\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| Adjusted Segment EBITDA | $ | 138,871\u00a0 | $ | 6,911\u00a0 | $ | 12,945\u00a0 | $ | 158,727\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 11,654\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (67,746) | ||||||||||||||||||||||
| Share-based compensation expense | (10,512) | ||||||||||||||||||||||
Transaction costs (1) | (7,629) | ||||||||||||||||||||||
| Depreciation and amortization | (18,591) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (13) | ||||||||||||||||||||||
| Interest expense, net | (70,141) | ||||||||||||||||||||||
| Loss before income tax expense (benefit) | $ | (4,251) | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 167,565\u00a0 | $ | 189,496\u00a0 | $ | 45,822\u00a0 | $ | 402,883\u00a0 | |||||||||||||||
| Intersegment revenue | 1,877\u00a0 | 73\u00a0 | 20\u00a0 | 1,970\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 169,442\u00a0 | $ | 189,569\u00a0 | $ | 45,842\u00a0 | $ | 404,853\u00a0 | |||||||||||||||
All other revenue | 5,277\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (1,970) | ||||||||||||||||||||||
Total consolidated revenue | $ | 408,160\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| Adjusted Segment EBITDA | $ | 45,701\u00a0 | $ | 6,445\u00a0 | $ | 6,364\u00a0 | $ | 58,510\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 3,549\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (24,336) | ||||||||||||||||||||||
| Share-based compensation expense | (4,960) | ||||||||||||||||||||||
Transaction costs (1) | (5,813) | ||||||||||||||||||||||
| Depreciation and amortization | (4,925) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (3) | ||||||||||||||||||||||
Change in fair value of warrants | 32,986\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (20,407) | ||||||||||||||||||||||
Income before income tax expense (benefit) | $ | 34,601\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 202,399\u00a0 | $ | 124,207\u00a0 | $ | 40,660\u00a0 | $ | 367,266\u00a0 | |||||||||||||||
| Intersegment revenue | 1,860\u00a0 | \u2014\u00a0 | 26\u00a0 | 1,886\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 204,259\u00a0 | $ | 124,207\u00a0 | $ | 40,686\u00a0 | $ | 369,152\u00a0 | |||||||||||||||
All other revenue | 9,134\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (1,886) | ||||||||||||||||||||||
Total consolidated revenue | $ | 376,400\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
Adjusted Segment EBITDA | $ | 61,494\u00a0 | $ | 1,609\u00a0 | $ | 3,138\u00a0 | $ | 66,241\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 3,609\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (23,252) | ||||||||||||||||||||||
| Share-based compensation expense | (3,515) | ||||||||||||||||||||||
Transaction costs (1) | (3,325) | ||||||||||||||||||||||
| Depreciation and amortization | (6,704) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (4) | ||||||||||||||||||||||
Interest expense, net | (24,330) | ||||||||||||||||||||||
Income before income tax expense (benefit) | $ | 8,720\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 512,735\u00a0 | $ | 528,443\u00a0 | $ | 124,930\u00a0 | $ | 1,166,108\u00a0 | |||||||||||||||
| Intersegment revenue | 5,195\u00a0 | 234\u00a0 | 63\u00a0 | 5,492\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 517,930\u00a0 | $ | 528,677\u00a0 | $ | 124,993\u00a0 | $ | 1,171,600\u00a0 | |||||||||||||||
All other revenue | 15,384\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (5,492) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,181,492\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| Adjusted Segment EBITDA | $ | 153,949\u00a0 | $ | 13,534\u00a0 | $ | 19,747\u00a0 | $ | 187,230\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 9,645\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (73,316) | ||||||||||||||||||||||
| Share-based compensation expense | (13,505) | ||||||||||||||||||||||
Transaction costs (1) | (13,358) | ||||||||||||||||||||||
| Depreciation and amortization | (15,584) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (160) | ||||||||||||||||||||||
Change in fair value of warrants | 25,344\u00a0 | ||||||||||||||||||||||
| Interest expense, net | (67,160) | ||||||||||||||||||||||
Income before income tax expense (benefit) | $ | 39,136\u00a0 | |||||||||||||||||||||
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| External revenue | $ | 536,857\u00a0 | $ | 333,284\u00a0 | $ | 115,777\u00a0 | $ | 985,918\u00a0 | |||||||||||||||
| Intersegment revenue | 4,848\u00a0 | \u2014\u00a0 | 78\u00a0 | 4,926\u00a0 | |||||||||||||||||||
Total revenue from reportable segments | $ | 541,705\u00a0 | $ | 333,284\u00a0 | $ | 115,855\u00a0 | $ | 990,844\u00a0 | |||||||||||||||
All other revenue | 28,649\u00a0 | ||||||||||||||||||||||
Eliminations of intersegment revenues | (4,926) | ||||||||||||||||||||||
Total consolidated revenue | $ | 1,014,567\u00a0 |
| (in thousands) | Senior | Healthcare Services | Life | Total | |||||||||||||||||||
| Adjusted Segment EBITDA | $ | 138,871\u00a0 | $ | 6,911\u00a0 | $ | 12,945\u00a0 | $ | 158,727\u00a0 | |||||||||||||||
All other Adjusted EBITDA | 11,654\u00a0 | ||||||||||||||||||||||
| Corporate & elimination of intersegment profits | (67,746) | ||||||||||||||||||||||
| Share-based compensation expense | (10,512) | ||||||||||||||||||||||
Transaction costs (1) | (7,629) | ||||||||||||||||||||||
| Depreciation and amortization | (18,591) | ||||||||||||||||||||||
| Loss on disposal of property, equipment, and software, net | (13) | ||||||||||||||||||||||
| Interest expense, net | (70,141) | ||||||||||||||||||||||
| Loss before income tax expense (benefit) | $ | (4,251) | |||||||||||||||||||||